Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells

Area of Science:

• Immunotherapy
• Oncology
• Hematology

Background:

• Peripheral T-cell lymphomas (PTCLs) are aggressive non-Hodgkin's lymphomas (NHLs) with poor prognoses.
• Current treatments for T-cell malignancies lack established standards of care, highlighting an urgent need for novel therapeutic strategies.
• Chimeric antigen receptor (CAR) immunotherapy has shown success in B-cell malignancies, offering hope for T-cell malignancies.

Purpose of the Study:

• To investigate the potential of CD4-targeted CAR immunotherapy using NK-92 cells for treating PTCLs.
• To develop and evaluate a novel third-generation anti-CD4 CAR construct (CD4CAR) in NK-92 cells.

Main Methods:

• A third-generation anti-CD4 CAR construct (CD4CAR) was engineered into clonal NK-92 cells.
• The efficacy of CD4CAR NK-92 cells was assessed against various CD4+ human T-cell leukemia and lymphoma cell lines (KARPAS-299, CCRF-CEM, HL60) and patient samples ex vivo.
• In vivo efficacy was evaluated using a KARPAS-299 cell model in mice.

Main Results:

• CD4CAR NK-92 cells demonstrated specific and robust elimination of diverse CD4+ T-cell leukemia and lymphoma cell lines and patient samples ex vivo.
• CD4CAR NK-92 cells effectively targeted KARPAS-299 cells in vivo, including difficult-to-access lymphoma nodules.
• Treatment with CD4CAR NK-92 cells significantly prolonged survival in the in vivo model.

Conclusions:

• CD4 is a suitable and uniformly expressed target for CAR immunotherapy in PTCLs.
• CD4CAR NK-92 cell immunotherapy represents a promising new therapeutic approach for PTCLs and other CD4+ T-cell malignancies.
• The study demonstrates the potential of CAR-modified NK cells for targeting CD4+ T-cell malignancies.